/
Biological products, (no diagnostic substances) company · DE · FY ends Dec · Revenue $23M · -27.27% margin · -$26M FCF
$8.39
$0.33 (-3.78%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 29.69% operating margin, ROIC at 128.41%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 6.3% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$51M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$23M
▼ -6.3% YoY
Net Income (TTM)
-$9M
▲ +138.3% YoY
Op. Margin
-27.27%
▲ +94.4pp YoY
ROIC
-36.19%
▲ +252.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▲ +26.1% YoY
Op. Cash Flow (TTM)
-$26M
▲ +25.9% YoY
Net Debt
$2M
Cash & Equiv.
$8M
3Y CAGR: +23.9%
Continue Research
Atara Biotherapeutics (ATRA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Atara Biotherapeutics scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Atara Biotherapeutics scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -27.3% operating margin and a -36.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ATRA's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.